Low-dose Radiotherapy in iNHL
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of low-dose radiotherapy (3 Gy\*4f) in indolent lymphoma.
Indolent Lymphoma|Low-dose Radiotherapy
RADIATION: Low-dose radiotherapy
Rate of clinical complete response after radiotherapy, complete resolution of disease in imaging or biopsy after low-dose radiotherapy, 6-month after radiotherapy
Overall response rate after radiotherapy, complete or partial resolution of disease in imaging or biopsy after low-dose radiotherapy, 6-month after radiotherapy|Progression-free survival rate at year 2 after enrollment, 2y-PFS, From enrollment to any disease progression or death, 2-year|Local control rate at year 2 after enrollment, 2y-LCR, From enrollment to any local disease progression or death, 2-year|Rate of acute toxicity (any and above grade 3), toxicities according to CTCAE criteria, From enrollment to 3 months after treatment|Rate of late toxicity (any and above grade 3), toxicities according to CTCAE criteria, After 3 months of enrollment|Quality of Life change, QoL, measurement basing on EORTC-QLQ-C30 tables, 1/3/6/12/24 months after radiotherapy
Biomarkers to predict radiotherapy efficacy, potential biomarkers in baseline tumor samples and blood samples, baseline/through study completion, an average of 1 year|Conjunctival microbiota, DNA samples from ocular adnexal extranodal MALT lymphoma patients' conjunctiva, baseline/4 fractions/1/3/6/12/24 months after radiotherapy
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of low-dose radiotherapy (3 Gy\*4f) in indolent lymphoma.